CAJ | 학술논문

紫杉醇在肺癌、胸腺癌、食道癌、淋巴瘤等多种肿瘤的治疗中得到广泛应用。但紫杉醇水溶性差，传统制剂采用聚氧乙烯蓖麻油(Cremophor EL)与无水乙醇(1：1)为增溶溶媒，临床使用中引起的不良反应较多。为提高紫杉醇制剂的治疗效果，降低不良反应，国内外学者致力于紫杉醇制剂学的研究。纳米制剂是现代药物制剂研究的前沿和热点，本文就紫杉醇纳米制剂的开发和应用进展进行综述。
자삼순재폐암、흉선암、식도암、림파류등다충종류적치료중득도엄범응용。단자삼순수용성차，전통제제채용취양을희비마유(Cremophor EL)여무수을순(1：1)위증용용매，림상사용중인기적불량반응교다。위제고자삼순제제적치료효과，강저불량반응，국내외학자치력우자삼순제제학적연구。납미제제시현대약물제제연구적전연화열점，본문취자삼순납미제제적개발화응용진전진행종술。
Paclitaxel is widely used in the treatment of lung cancer, breast cancer, esophageal cancer,lymphoma and other tumor. Clinical use of paclitaxel is limited by its poor aqueous solubility. Cremophor EL and ethanol ( 1 :1 ) are used as solvent in traditional administration of paclitaxel. However, Cremophor EL has adverse reactions in clinic. Some alternative formulations have been studied to increase its therapeutic index and decrease toxicity and hypersensitivity. Nanoparticle formulation is the frontier and focus of modern pharmaceutical drug delivery system. In this paper,the latest development and application of paclitaxel nanoparticle formulations were reviewed.